Donald Trump mocks PM Modi for funding library in Afghanistan

Agencies
January 3, 2019

US President Donald Trump on Wednesday mocked Indian Prime Minister Narendra Modi for funding a library in Afghanistan, suggesting it was of no use.

Trump brought up India's aid during a rambling press appearance at a cabinet meeting as he defended his push for the United States to invest less overseas.

While stating that he got along with Modi, Trump said the Indian leader was "constantly telling me he built a library in Afghanistan."

"You know what that is? That's like five hours of what we spend," Trump said.

"And we're supposed to say, 'Oh, thank you for the library.' I don't know who's using it in Afghanistan," Trump said.

It was unclear to which project Trump was referring, but India has committed $3 billion in assistance to Afghanistan since US-led forces toppled the Taleban regime after the September 11, 2001 attacks.

Projects have included the reconstruction of an elite high school in Kabul and scholarships to India for 1,000 Afghan students each year.

Inaugurating the Afghan parliament building in 2015 after reconstruction financed by India, Modi promised to promote programs "empowering Afghan youth with modern education and professional skills."

India has been one of the most enthusiastic countries over the US mission in Afghanistan.

Trump last month moved to pull all 2,000 US troops out of Syria and cut by half the 14,000-strong force in Afghanistan, calling for less spending overseas.

Alluding in Wednesday's remarks to the 1979-1989 Soviet occupation of Afghanistan, Trump said: "Russia used to be the Soviet Union. Afghanistan made it Russia because they went bankrupt fighting in Afghanistan."

Comments

SD
 - 
Thursday, 3 Jan 2019

Modi giving only for publicity. Modi spending taxpayers money in other countries, while people throught India are starving to death.

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 30,2020

Mumbai, Apr 30: Rishi Kapoor, the romantic star of many a Bollywood film who was diagnosed with leukemia in 2018, died in a Mumbai hospital on Thursday, his brother Randhir Kapoor said. He was 67.

Rishi, a third generation actor of the famous Kapoor dynasty, is survived by his wife Neetu Kapoor, actor son Ranbir and daughter Ridhima.

"He is no more. He has passed away," Randhir said.

Rishi was taken to the H N Reliance hospital by his family on Wednesday.

His death comes a day after after his "D-Day" co-star Irrfan Khan passed away, also of cancer. Three months ago, the disease claimed his sister Ritu Nanda.

"Our dear Rishi Kapoor passed away peacefully at 8:45am IST in hospital today after a two-year battle with leukemia. The doctors and medical staff at the hospital said he kept them entertained to the last.

He remained jovial and determined to live to the fullest right through two years of treatment across two continents. Family, friends, food and films remained his focus and everyone who met him during this time was amazed at how he did not let his illness get the better of him, the family said in a statement.

Rishi returned to India last September after undergoing treatment for his cancer in the US for almost a year.

In February, he was hospitalised twice.

He was first admitted to a hospital in Delhi where he was attending a family function. At the time, he had said he was suffering from an "infection".

After his return to Mumbai, he was again admitted to a hospital with viral fever. He was discharged soon after.

Rishi made his first screen appearance as a child artiste in his father Raj Kapoor's film Shri 420 , where he appeared in the song Pyaar hua ekraar hua . This was followed by "Mera Naam Joker". But it was in 1973, with the blockbuster Bobby , again directed by his father, that he made his debut as a romantic hero. He continued to be a favourite romantic hero for almost three decades.

His notable films as a romantic hero are "Laila Majnu", "Rafoo Chakkar", "Karz", "Chandni", "Heena" and "Saagar".

He was, however, more proud of his second innings as an actor, which he found more satisfying. His notable films as a character artiste are "Do Dooni Chaar" with wife Neetu, "Agnipath" and "Kapoor & Sons".

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 9,2020

Paris, Apr 9: More than 1.5 million cases of the novel coronavirus have been registered worldwide, according to a tally compiled by AFP at 0530 GMT Thursday from official sources.

Of the 1,502,478 infections, 87,320 people have died across 192 countries and territories since the epidemic first emerged in China late last year.

The tallies, using data collected by AFP from national authorities and information from the World Health Organization (WHO), probably reflect only a fraction of the actual number of infections. Many countries are only testing the most serious cases.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 10,2020

Melbourne, Apr 10: Scientists have identified six drug candidates from more than 10,000 compounds that may help treat COVID-19.

The research, published in the journal Nature, tested the efficacy of approved drugs, drug candidates in clinical trials and other compounds.

"Currently there are no targeted therapeutics or effective treatment options for COVID-19," said Professor Luke Guddat from the University of Queensland in Australia.

"In order to rapidly discover lead compounds for clinical use, we initiated a programme of high-throughput drug screening, both in laboratories and also using the latest computer software to predict how different drugs bind to the virus," Guddat said.

The project targeted the main COVID-19 virus enzyme, known as the main protease or Mpro, which plays a pivotal role in mediating viral replication, the researchers said.

This makes it an attractive drug target for this virus, and as people don't naturally have this enzyme, compounds that target it are likely to have low toxicity, they said.

"We add the drugs directly to the enzyme or to cell cultures growing the virus and assess how much of each compound is required to stop the enzyme from working or to kill the virus. If the amount is small, then we have a promising compound for further studies," said Guddat.

After assaying thousands of drugs, researchers found of the six that appear to be effective in inhibiting the enzyme, one is of particular interest.

"We're particularly looking at several leads that have been subjected to clinical trials including for the prevention and treatment of various disorders such as cardiovascular diseases, arthritis, stroke, atherosclerosis and cancer," Guddat said.

Researchers said compounds that are already along the pipeline to drug discovery are preferred, as they can be further tested as antivirals at an accelerated rate compared to new drug leads that would have to go through this process from scratch.

"With continued and up-scaled efforts we are optimistic that new candidates can enter the COVID-19 drug discovery pipeline in the near future," Guddat said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.